Novel Antiplatelet and Antithrombotic Agents in the Treatment of Non-ST-Segment Elevation Coronary Ischemia

  • M. Musa Khan
  • Neal S. Kleiman
Part of the Contemporary Cardiology book series (CONCARD)


The relationship between coronary artery disease and intravascular thrombosis has intrigued cardiologists for almost a century. In the early 1960s, Friedman and Van den Bovenkamp described the pathology of arterial thrombus as consisting of a platelet-rich core and a fibrin-rich tail (1). However, the significance of arterial thrombus was debated over the next 15 years until De Wood et al. (2), in 1980, reported occlusive coronary thrombosis in 87% of patients presenting within 6 h of acute transmural myocardial infarction, initiating the era of thrombolysis and coronary revascularization in the treatment of acute transmural myocardial infarction.


Acute Coronary Syndrome Platelet Aggregation Unstable Angina Unfractionated Heparin Thrombin Generation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Friedman M, Van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am J Pathol 1966; 48: 19–44.PubMedGoogle Scholar
  2. 2.
    DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897–902.PubMedGoogle Scholar
  3. 3.
    TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest: results of the thrombolysis in myocardial ischemia (TIMI IIIA) trial. Circulation 1993; 87: 38–52.Google Scholar
  4. 4.
    Roberts R, Kleiman NS. Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a `new diagnostic mind-set. ’ Circulation 1994; 89: 872–881.PubMedGoogle Scholar
  5. 5.
    Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996; 335: 1333–1341.PubMedGoogle Scholar
  6. 6.
    Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342–1349.PubMedGoogle Scholar
  7. 7.
    Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO HA Investigators. N Engl J Med 1996; 335: 1333–1341.PubMedGoogle Scholar
  8. 8.
    The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparision of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Circulation 1994; 89: 1545–1556.Google Scholar
  9. 9.
    Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045–2048.PubMedGoogle Scholar
  10. 10.
    Theroux P. Antiplatelet and antithrombotic therapy in unstable angina. Am J Cardiol 1991; 68: 92B–98B.PubMedGoogle Scholar
  11. 11.
    Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley K, et al. Unstable angina: diagnosis and management. Clin Prac Guideline 1994; 10.Google Scholar
  12. 12.
    Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al. Aspirin sulifnpyrazone, or both in unstable angina: results of a Canadian Multicenter trial. N Engl J Med 1985; 313: 1369–1375.PubMedGoogle Scholar
  13. 13.
    Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE III, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396–403.PubMedGoogle Scholar
  14. 14.
    Theroux P, Quimet H, McCans J, Latour J, Joly P, Levy G, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–1111.PubMedGoogle Scholar
  15. 15.
    The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–830.Google Scholar
  16. 16.
    Topol EJ. Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 1995; 75: 27B–33B.PubMedGoogle Scholar
  17. 17.
    Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377–381.PubMedGoogle Scholar
  18. 18.
    Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125–2131.PubMedGoogle Scholar
  19. 19.
    Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775–778.PubMedGoogle Scholar
  20. 20.
    Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941–944.PubMedGoogle Scholar
  21. 21.
    Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562–1569.PubMedGoogle Scholar
  22. 22.
    Annex BH, Denning SM, Channon KM, Sketch MH Jr, Stack RS, Morrissey JH, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619–622.PubMedGoogle Scholar
  23. 23.
    Barstad RM, Hamers MJ, Kierulf P, Westvik AB, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/factor VIIa-dependent platelet-thrombus formation when exposed to flowing nonanticoagulated human blood. Arterioscler Thromb Vasc Biol 1995; 15: 11–16.PubMedGoogle Scholar
  24. 24.
    Plotnick GD, Fisher ML, Lerner B, Carliner NH, Peters RW, Becker LC. Collateral circulation in patients with unstable angina. Chest 1982; 82: 719–725.PubMedGoogle Scholar
  25. 25.
    Ahmed WH, Bittl JA, Braunwald E. Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparision with that in stable angina. Am J Cardiol 1993; 72: 544–550.PubMedGoogle Scholar
  26. 26.
    Falk E, et al. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1986; 73: 418–427.Google Scholar
  27. 27.
    Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983–989.PubMedGoogle Scholar
  28. 28.
    Biagini A, Mazzei M, Carpeggiani C, Testa R, Antonelli R, Michelassi C, et al. Vasospastic ischemic mechanism of frequent asymptomatic transient ST-T changes during continuous electrocardiographic monitoring in selected unstable angina patients. Am Heart J 1982; 103: 13–20.PubMedGoogle Scholar
  29. 29.
    Anderson HV, Kirkeeide RL, Krishnaswami A, Weigelt LA, Revana M, Weisman HF, et al. Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 1994; 23: 1031–1037.PubMedGoogle Scholar
  30. 30.
    Folts JD, Gallagher K, Rowe GG. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation 1982; 65: 248–255.PubMedGoogle Scholar
  31. 31.
    Moise A, Theroux P, Taeymans Y, Descoings B, Lesperance J, Waters DD, et al. Unstable angina and progression of coronary atherosclerosis. N Engl J Med 1983; 309: 685–689.PubMedGoogle Scholar
  32. 32.
    Williams AE, Freeman MR, Chisholm RJ, Patt NL, Armstrong PW. Angiographic morphology in unstable angina. Am J Cardiol 1988; 62: 1024–1027.PubMedGoogle Scholar
  33. 33.
    Bugiardini R, Pozzati A, Borghi A, Morgagni GL, Ottani F, Muzi A, et al. Angiographic morphology in unstable angina and its relation to transient myocardial ischemia and hospital outcome. Am J Cardiol 1991; 67: 460–464.PubMedGoogle Scholar
  34. 34.
    Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina. Circulation 1989; 80: 17–23.PubMedGoogle Scholar
  35. 35.
    Sansa M, Cernigliaro C, Bolognese L, Bongo SA, Rossi L, Rossi P. Angiographic morphology and response to therapy in unstable angina. Clin Cardiol 1988; 11: 121–126.PubMedGoogle Scholar
  36. 36.
    Ambrose JA, Winters SL, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986; 7: 472–478.PubMedGoogle Scholar
  37. 37.
    Lesperance J, Theroux P, Hudon G, Waters D. A new look at coronary angiograms: plaque morphology as a help to diagnosis and to evaluate outcome. Int J Card Imaging 1994; 10: 75–94.PubMedGoogle Scholar
  38. 38.
    Kragel AH, Gertz SD, Roberts WC. Morphologic comparison of frequency and types of acute lesions in the major epicardial coronary arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction. J Am Coll Cardiol 1991; 18: 801–808.PubMedGoogle Scholar
  39. 39.
    Ambrose JA, Winter SL, Stern A, Eng A, Teichholz LE, Gorlin R, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1987; 9: 1397–1402.PubMedGoogle Scholar
  40. 40.
    Alison HW, Russel RO Jr, Mantel JA, Kouchoukos NT, Moraski RE, Rackley CE. Coronary anatomy and arteriography in patients with unstable angina pectoris. Am J Cardiol 1978; 41: 204–209.PubMedGoogle Scholar
  41. 41.
    Anonymous. Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography in in-hospital cardiac events. Circulation 1989; 80: 17–23.Google Scholar
  42. 42.
    Gotoh K, Minamino T, Katoh O, Hamano Y, Fukui S, Hori M, et al. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation 1988; 77: 526–534.PubMedGoogle Scholar
  43. 43.
    Holmes DR Jr, Hartzler GO, Smith HC, Fuster V. Coronary artery thrombosis in patients with unstable angina. Br Heart J 1981; 45: 411–416.PubMedGoogle Scholar
  44. 44.
    Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315: 913–919.PubMedGoogle Scholar
  45. 45.
    Steele PM, Chesebro JH, Stanson AW, Holmes DR Jr, Dewanjee MK, Badimon L, et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105–112.PubMedGoogle Scholar
  46. 46.
    Marguerie GA, Plow EF. The fibrinogen-dependent pathway of platelet aggregation. Ann NY Acad Sci 1983; 408: 556–566.PubMedGoogle Scholar
  47. 47.
    Marguerie GA, Thomas-Maison N, Larrieu MJ, Plow EF. The interaction of fibrinogen with human platelets in a plasma milieu. Blood 1982; 59: 91–95.PubMedGoogle Scholar
  48. 48.
    Turitto VT, Weiss HJ, Zimmerman TS, Sussman II. Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood 1985; 65: 823–831.PubMedGoogle Scholar
  49. 49.
    Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993; 81: 1263–1276.PubMedGoogle Scholar
  50. 50.
    Sakariassen KS, Nievelstein PF, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins lb and IIb-IIIa in platelet adherence to human artery subendothelium. B J Haematol 1986; 63: 681–691.Google Scholar
  51. 51.
    Coller BS, Beer JH, Scudder LE, Steinberg MH. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood 1989; 74: 182–192.PubMedGoogle Scholar
  52. 52.
    Ross JM, McIntire LV, Moake JL, Rand JH. Platelet adhesion and aggregation on human type VI collagen surfaces under physiological flow conditions. Blood 1995; 85: 1826–1835.PubMedGoogle Scholar
  53. 53.
    Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559–1562.PubMedGoogle Scholar
  54. 54.
    Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 1989; 80: 1766–1774.PubMedGoogle Scholar
  55. 55.
    Kaplan AV, Leung LL, Leung WH, Grant GW, McDougall IR, Fischell TA. Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model. Circulation 1991; 84: 1279–1288.PubMedGoogle Scholar
  56. 56.
    D’ Souza SE, Ginsberg MH, Burke TA, Lam SC, Plow EF. Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science 1988; 242: 91–93.PubMedGoogle Scholar
  57. 57.
    Niya K, Hodson E, Bader R, Byers-Ward V, Koziol J, Plow E, Increased surface expression of the membrane glycoprotein IIb/Illa complex induced by platelet activation, relationship to the binding of fibrinogen and platelet aggregation. Blood 1987; 70: 475–483 (abstract).Google Scholar
  58. 58.
    Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907–914.PubMedGoogle Scholar
  59. 59.
    Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/Illa complex. J Clin Invest 1985; 76: 101–108.PubMedGoogle Scholar
  60. 60.
    O’Toole TE, Katagiri Y, Faull RJ, Peter K, Tamura R, Quaranta V, et al. Integrin cytoplasmic domains mediate inside-out signal transduction. J Cell Biol 1994; 124: 1047–1059.PubMedGoogle Scholar
  61. 61.
    Ishihara H, Kahn ML, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516–519.PubMedGoogle Scholar
  62. 62.
    Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502–506.PubMedGoogle Scholar
  63. 63.
    Lerner DJ, Chen M, Tram T, Coughlin SR. Agonist recognition by proteinase-activated receptor 2 and thrombin receptor. Importance of extracellular loop interactions for receptor function. J Biol Chem 1996; 271: 13943–13947.PubMedGoogle Scholar
  64. 64.
    Molino M, Bainton DF, Hoxie JA, Coughlin SR, Brass LF. Thrombin receptors on human platelets. Initial localization and subsequent redistribution during platelet activation. J Biol Chem 1997; 272: 6011–6017.PubMedGoogle Scholar
  65. 65.
    Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand’s disease and the Bernard-Soulier syndrome. J Lab Clin 1978; 92: 750–764.Google Scholar
  66. 66.
    Reverter JC, Beguin S, Kessels H, Kumar R, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 Antibody. J Clin Invest 1996; 98: 863–874.PubMedGoogle Scholar
  67. 67.
    Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177–1184.PubMedGoogle Scholar
  68. 68.
    Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J of Cardiol 1995; 11: 221–227.Google Scholar
  69. 69.
    Funk CD, Furci L, Moran N, Fitzgerald GA. Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. Mol Pharm1993; 44: 934–939.Google Scholar
  70. 70.
    ISIS-2 (Second International Study of Infarct Survival). Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349–360 (abstract).Google Scholar
  71. 71.
    De Caterina R, Giannessi D, Bernini W, Gazzetti P, Michelassi C, L’ Abbate A, et al. Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. Am J Cardiol 1985; 55: 589–590.PubMedGoogle Scholar
  72. 72.
    Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 800–805.Google Scholar
  73. 73.
    Clarke RJ, Mayo G, Price P, Fitzgerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137–1141.PubMedGoogle Scholar
  74. 74.
    Anonymous. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br. Med. J. Clin. Res. 1994; 1988: 316–320.Google Scholar
  75. 75.
    Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 1993; 82: 505–512.PubMedGoogle Scholar
  76. 76.
    Folts JD, Crowell EB Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365–370.PubMedGoogle Scholar
  77. 77.
    The RAPT Investigators. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89: 588–595.Google Scholar
  78. 78.
    Rehse K, Ciborski T. Platelet aggregation inhibiting and anticoagulant effects of oligoamine, XXVI: antiplatelet and antithrombotic effects of the oligoamine RE 1492 in combination with standard and future antithrombotic drugs. Arch Pharm 1995; 328: 333–337.Google Scholar
  79. 79.
    De La Cruz JP, Villalobos MA, Garcia PJ, Smith-Agreda JM, Sanchez de la Cuesta F. Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers. Eur J Clin Pharm 1995; 47: 497–502.Google Scholar
  80. 80.
    De La Cruz JP, Mata JM, Sanchez de la Cuesta F. Triflusal vs aspirin on the inhibition of human platelet and vascular cyclooxygenase. Gen Pharmacol 1992; 23: 297–300.PubMedGoogle Scholar
  81. 81.
    Plaza L, Lopez-Bescos L, Martin-Jadraque L, Alegria E, Cruz-Fernandez JM, Velasco J, et al. Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial. Grupo de Estudio del Triflusal en la Angina Inestable. Cardiology 1993; 82: 388–398.PubMedGoogle Scholar
  82. 82.
    Rudd MA, George D, Amarante P, Vaughan DE, Loscalzo J. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ Res 1990; 67: 1175–1181.PubMedGoogle Scholar
  83. 83.
    Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, et al. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group J Am Coll Cardiol 1989; 14: 877–884.Google Scholar
  84. 84.
    Kerins DM, Roy L, Kunitada S, Adedoyin A, Fitzgerald GA, Fitzgerald DJ. Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. [Published erratum appears in Circulation 1992 86:698.] Circulation 1992; 85: 526–532.Google Scholar
  85. 85.
    Kerins DM, Murray R, Fitzgerald GA. Prostacyclin and prostaglandin El: molecular mechanisms and therapeutic utility. Prog Hemost Thromb 1991; 10: 307–337.PubMedGoogle Scholar
  86. 86.
    Suzuka H, Fujiwara H, Tanaka M, Yoshifusa H, Nakamura Y, Shibata Y. Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. J Cardiovasc Pharmacol 1995; 25: 9–13.PubMedGoogle Scholar
  87. 87.
    Tohgi H, Takahashi H, Kashiwaya M, Watanabe K. Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin. Stroke 1994; 25: 2017–2021.PubMedGoogle Scholar
  88. 88.
    Uchiyama S, Yamazaki M, Maruyama S, Handa M, Ikeda Y, Fukuyama M, et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994; 25: 1547–1551.PubMedGoogle Scholar
  89. 89.
    Cattaneo M, Akkawat B, Kinlough-Rathbone RL, Packham MA, Cimminiello C, Mannucci PM. Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin. Thromb Haemost 1994; 71: 91–94.PubMedGoogle Scholar
  90. 90.
    Defreyn G, Bernat A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine: a review. Semin Thromb Hemost 1989; 15: 159–166.PubMedGoogle Scholar
  91. 91.
    Haynes RB, Sandler RS, Larson EB, Pater JL, Yatsu FM. A critical appraisal of ticlopidine, a new antiplatelet agent: effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992; 152: 1376–1380.PubMedGoogle Scholar
  92. 92.
    Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 1993; 13: 393–397.PubMedGoogle Scholar
  93. 93.
    Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Investigat 1985; 75: 328–338.Google Scholar
  94. 94.
    Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Mannucci PM. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost 1991; 66: 694–699.PubMedGoogle Scholar
  95. 95.
    Roald HE, Barstad RM, Kierulf P, Skjorten F, Dickinson JP, Kieffer G, et al. Clopidogrel-a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 1994; 71: 655–662.PubMedGoogle Scholar
  96. 96.
    Yao SK, Ober JC, Ferguson JJ, Maffrand JP, Anderson HV, Buja LM, et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267: H488–93.PubMedGoogle Scholar
  97. 97.
    Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–1220.PubMedGoogle Scholar
  98. 98.
    Gent M, Beaumont D, Blanchard J, Bousser MG, Coffman J, Easton JD, et al. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of Ischaemic Events (CAPRIE). Lancet 1996; 348: 1329–1339.Google Scholar
  99. 99.
    Schafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199–209.PubMedGoogle Scholar
  100. 100.
    Coller BS, Peerschke EI, Seligsohn U, Scudder LE, Nurden AT, Rosa JP. Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb-IIIa complex receptor. J Lab Clin Med 1986; 107: 384–392.PubMedGoogle Scholar
  101. 101.
    Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993; 268: 1066–1073.PubMedGoogle Scholar
  102. 102.
    Scarborough RM, Rose JW, Naughton MA, Phillips DR, Nannizzi L, Arfsten A, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 1993; 268: 1058–1065.PubMedGoogle Scholar
  103. 103.
    Sheu JB, Ko WC, Hung WC, Peng HC, Huang TF. Interaction of thrombin-activated platelets with extracellular matrices (fibronectin and vitronectin): comparison of the activity of Arg-Gly-Asp-containing venom peptides and monoclonal antibodies against glycoprotein IIb/IIIa complex. J Pharm Pharmacol 1997; 49: 78–84.PubMedGoogle Scholar
  104. 104.
    Trikha M, Rote WE, Manley PJ, Lucchesi BR, Markland FS. Purification and characterization of platelet aggregation inhibitors from snake venoms. Thromb Res 1994; 73: 39–52.PubMedGoogle Scholar
  105. 105.
    Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302–308.PubMedGoogle Scholar
  106. 106.
    Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein Ilb/IIIa complex. J Clin Invest 1985; 76: 101–108.PubMedGoogle Scholar
  107. 107.
    Coller BS, Scudder LE. Inhibition of dog platelet function by in vivo infusion of F(ab’)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 1985; 66: 1456 1459.Google Scholar
  108. 108.
    Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, et al. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 1995; 91: 1354–1362.PubMedGoogle Scholar
  109. 109.
    Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783–786.PubMedGoogle Scholar
  110. 110.
    Mickelson JK, Simpson PI, Lucchesi BR. Antiplatelet monoclonal F(ab’)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989; 21: 393–405.PubMedGoogle Scholar
  111. 111.
    Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670–677.PubMedGoogle Scholar
  112. 112.
    Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, et al. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb 1993; 13: 1837–1842.PubMedGoogle Scholar
  113. 113.
    Mickelson JK, Simpson PI, Cronin M, Homeister JW, Laywell E, Kitzen J, et al. Antiplatelet antibody [7E3 F(ab’)2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation 1990; 81: 617–627.PubMedGoogle Scholar
  114. 114.
    Yasuda T, Gold HK, Fallon IT, Leinbach RC, Guerrero JL, Scudder LE, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/Illa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81: 1284 1291.Google Scholar
  115. 115.
    Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757–1764.PubMedGoogle Scholar
  116. 116.
    Kiss RG, Lu HR, Roskams T, Jang IK, Plow EF, Gold HK, et al. Time course of the effects of a single bolus injection of F(ab’)2 fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation, and bleeding time in dogs. Arterioscler Thromb 1994; 14: 367–374.PubMedGoogle Scholar
  117. 117.
    Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993; 22: 381–389.PubMedGoogle Scholar
  118. 118.
    Gold H, Gimple L, Yasuda T, Leinbach R, Werner W, Holt R, et al. Pharmacodynamic study of F(ab’) 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651–659.PubMedGoogle Scholar
  119. 119.
    Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, et al. Pharmacodynamic study of F(ab’)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651–659.PubMedGoogle Scholar
  120. 120.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIlb/ IIIa receptors. J Am Coll Cardiol 1995; 26: 1665–1671.PubMedGoogle Scholar
  121. 121.
    Simoons ML, Jan de Boer M, Van den Brand MJBM, Van Miltenburg AJ, Hoorntje JCA, Heyndrickx GR, et al., and the European Cooperative Study Group. Randomized trial of a GPIIB/IIIA platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596–603.PubMedGoogle Scholar
  122. 122.
    The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/ IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–961.Google Scholar
  123. 123.
    Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 1434–1435.Google Scholar
  124. 124.
    EPILOG Investigators T. Platelet glycoprotein llb/IIIa receptor blockade with abciximab with low dose heparin during percutaneous transluminal angioplasty. N Engl J Med 1997; 336: 1689–1696.Google Scholar
  125. 125.
    The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina-the CAPTURE Study. Lancet 1997; 349: 1429 1435.Google Scholar
  126. 126.
    Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/ IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222–1227.PubMedGoogle Scholar
  127. 127.
    Schulman SP, Goldschmidt-Clerand PJ, Navetta FI, Chandra NC, Guerci AD, Califf RM, et al. Integrilin in unstable angina: a double-blind randomized trial. Circulation 1993; 88 (Suppl I): I-608 (abstract).Google Scholar
  128. 128.
    The IMPACT-2 Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention-IMPACT-II. Lancet 1997; 349: 1422–1428.Google Scholar
  129. 129.
    Phillips D, et al. Circulation 1997 in press.Google Scholar
  130. 130.
    The PURSUIT Investigators. Results of the PURSUIT trial of integrilin in patients with acute coronary syndromes of unstable angina and NQWMI. Presented at Stockholm, 1997 (abstract).Google Scholar
  131. 131.
    Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharm Ther 1994; 56: 377–388.Google Scholar
  132. 132.
    Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man Circulation 1993; 88: 1512–1517.Google Scholar
  133. 133.
    The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 1445–1453.Google Scholar
  134. 134.
    The Prism Study Group. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New Engl J Med 1998; 338: 1498–1505.Google Scholar
  135. 134a.
    The Prism Plus Study Group. Inhibition of the platelet glycoprotein IIb/IIIa reception in unstable angina and non-Q-wave myocardial infarction. New Engl J Med 1998; 338: 1488–1497.Google Scholar
  136. 135.
    Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadvary P, et al. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 1996; 39: 3139–3147.PubMedGoogle Scholar
  137. 136.
    Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, et al. Platelet membrane receptor glycoprotein IIb/Illa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996; 94: 899–905.PubMedGoogle Scholar
  138. 137.
    Topol E, Califf R, Vandewerf F, Diaz R, Paolasso E, Aylward P, et al. International, randomized, controlled trial of lamifiban (a platelet glycoprotein llb/Illa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386–2395.Google Scholar
  139. 138.
    Szalony JA, Haas NF, Salyers AK, Taite BB, Nicholson NS, Mehrotra DV, et al. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 1995; 91: 411–416.PubMedGoogle Scholar
  140. 139.
    Bovy PR, Tjoeng FS, Rico JG, Rogers TE, Lindmark RJ, Zablocki JA, et al. Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents. Bioorganic Med Chem 1994; 2: 881–895.Google Scholar
  141. 140.
    Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IiB/IiiA antagonist, and its orally active prodrug, lefradafiban, in men. Circulation 1997; 96: 1130–1138.PubMedGoogle Scholar
  142. 141.
    Simpfendorfer C, Kandice K, lowrie M, Anders RJ, Burns DM, Miller DP, et al. first chronic platelet glycoptrotein IIb-IIIa integrin blockade: a randomized, placebo controlled pilot study of xemlofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96: 76–81.PubMedGoogle Scholar
  143. 142.
    Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, et al. Sustained platelet glycoprotein Iib/Iiia blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997; 96: 1117–1121.PubMedGoogle Scholar
  144. 143.
    Kereiakes DJ, Runyon JP, Kleiman NS, Higby NS, Anderson LC, Hantsbarger G, et al. Differential dose-response to oral xemlofiban after antecedent intravenous abciximab: administration for complex coronary interventions. Circulation 1997; 94: 906–910.Google Scholar
  145. 143a.
    Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIla antagonist, sibrofiban, in patients after an acute coronary syndrome. Results of the TIMI 12 Trial. Circulation 1998; 97: 340–349.PubMedGoogle Scholar
  146. 144.
    Rapold HJ, de Bono D, Arnold AE, Arnout J, De Cock F, Collen D, et al. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group. Circulation 1992; 85: 928–934.PubMedGoogle Scholar
  147. 145.
    Biasucci LM, Liuzzo G, Caligiuri G, Quaranta G, Andreotti F, Sperti G, et al. Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Circulation 1996; 93: 2121–2127.PubMedGoogle Scholar
  148. 146.
    al-Nozha M, Gader AM, al-Momen AK, Noah MS, Jawaid M, Arafa M. Haemostatic variables in patients with unstable angina. Int J Cardiol 1994; 43: 269–277.PubMedGoogle Scholar
  149. 147.
    Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988; 263: 3823–3834.PubMedGoogle Scholar
  150. 148.
    Hatton MW, Moar SL, Richardson M. Deendothelialisation in vivo initiates a thrombogenic reaction at the rabbit aorta surface: correlation of uptake of fibrinogen and antithrombin-III wiht thrombin generation by the exposed endothelium. Am J Pathol 1989;499–508 (abstract).Google Scholar
  151. 149.
    Manolis AS, Melita-Manolis H, Stefanadis CU. Plasma level changes of fibrinopeptide A after uncomplicated coronary angioplasty. Clin Cardiol 1993; 16: 548–552.PubMedGoogle Scholar
  152. 150.
    Eritsland J, Seljeflot I, Arnesen H, Smith P, Westvik AB. Effects of long-term treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease. Thromb Res 1992; 66: 55–60.PubMedGoogle Scholar
  153. 151.
    Haaland AK, Skjonsberg OH, Gravem K, Ruyter R, Godal HC. Comparison of thrombin-antithrombin complex (TAT) levels and fibrinopeptide A following thrombin incubation of human plasma using hirudin as an inhibitor of TAT formation. Thromb Res 1991; 61: 253–259.PubMedGoogle Scholar
  154. 152.
    Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc the Natl Acad Sci USA 1989; 86: 3619–3623.Google Scholar
  155. 153.
    Callas DD, Fareed J. Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy. Thromb Res 1995; 78: 457–460.PubMedGoogle Scholar
  156. 154.
    Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans. Thromb Res 1994; 75: 609–616.PubMedGoogle Scholar
  157. 155.
    Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161–182.PubMedGoogle Scholar
  158. 156.
    Abildgaard U, Lindahl AK, Sandset PM. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis 1991; 21: 254–257.PubMedGoogle Scholar
  159. 157.
    Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1: 1225–1228.PubMedGoogle Scholar
  160. 158.
    Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24: 39–45.PubMedGoogle Scholar
  161. 159.
    Gurfinkel EP, Manos EJ, Mej ail RI, Cerda MA, Duronto EA, Garcia CN, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313–318.PubMedGoogle Scholar
  162. 160.
    Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91: 1929–1935.PubMedGoogle Scholar
  163. 161.
    Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141–145.PubMedGoogle Scholar
  164. 162.
    Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639–643.PubMedGoogle Scholar
  165. 163.
    Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 1993; 119: 874–881.PubMedGoogle Scholar
  166. 164.
    Flaker GC, Bartolozzi J, Davis V, McCabe C, Cannon CP. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. Arch Intern Med 1994; 154: 1492–1496.PubMedGoogle Scholar
  167. 165.
    Becker RC, Cannon CP, Tracy RP, Thompson B, Bovill EG, Desvigne-Nickens P, et al. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Am Heart J 1996; 131: 421–433.PubMedGoogle Scholar
  168. 166.
    Granger CB, Califf RM, Van de Werf F, White HD, Topol EJ. Activated partial thromboplastin time and clinical outcome among patients with unstable angina or non Q-wave MI treated with intravenous heparin. Circulation 1996; 93: 870–878 (abstract).PubMedGoogle Scholar
  169. 167.
    Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 1–9.Google Scholar
  170. 168.
    Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625–630.PubMedGoogle Scholar
  171. 169.
    Kijowski R, Hoppensteadt D, Walenga J, Borris L, Lassen MR, Fareed J. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin. Thromb Res 1994; 74: 53–64.PubMedGoogle Scholar
  172. 170.
    Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995; 77: 175–185.PubMedGoogle Scholar
  173. 171.
    Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23 (suppl 1): 103–106.PubMedGoogle Scholar
  174. 172.
    Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinol 1995; 6 (suppl 1): S57–64.Google Scholar
  175. 173.
    Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular-weight heparin in rabbits. Blood 1982; 59: 1239.PubMedGoogle Scholar
  176. 174.
    Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994; 72: 330–334.PubMedGoogle Scholar
  177. 175.
    Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Lowmolecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152–156.PubMedGoogle Scholar
  178. 176.
    Anonymous. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347: 561–568.Google Scholar
  179. 177.
    Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, et al. Comparison of low-molecularweight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease-Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61–68.PubMedGoogle Scholar
  180. 178.
    TIMI Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 1lA Trial Investigators. J Am Coll Cardiol 1997; 29: 1474–1482.Google Scholar
  181. 179.
    Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, et al. A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–452.PubMedGoogle Scholar
  182. 180.
    Eitzman DT, Chi L, Schwartz RS, Lucchesi BR. Heparin neutralization by platelet-rich thrombi: role of platelet factor 4. Circulation 1994; 89: 1523–1529.PubMedGoogle Scholar
  183. 181.
    Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation 1994; 89: 1523–1529.PubMedGoogle Scholar
  184. 182.
    Johnson PH: Hirudin. clinical potential of a thrombin inhibitor. Annu Rev Med 1994; 45: 165–177.PubMedGoogle Scholar
  185. 183.
    Phaneuf MD, Ito RK, LoGerfo FW. Synthesis and characterization of a recombinant hirudin-albumin complex. Blood Coagul Fibrinol 1994; 5: 641–645.Google Scholar
  186. 184.
    Gallistl S, Muntean W. Thrombin-hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma. Thromb Haemost 1994; 72: 387–392.PubMedGoogle Scholar
  187. 185.
    Markwardt F, Nowark G, Sturzebecher J, Griebach U, Walsmann P, Vogel G. Pharmocokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984; 52: 160–163.PubMedGoogle Scholar
  188. 186.
    Cardot JM, Lefevre Gy, Godbillon JA. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration. J Pharm Biopharm 1994; 22: 156–147.Google Scholar
  189. 187.
    Talbot M. Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis. Semin Thromb Hemost 1995; 15: 293–301.Google Scholar
  190. 188.
    Lam JY, Chesebro JH, Steele PM, Heras M, Webster MW, Badimon L, et al. Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. Circulation 1991; 84: 814–820.PubMedGoogle Scholar
  191. 189.
    Nowak G. Pharmacokinetics of hirudin. Semin Thromb Hemost 1991; 17: 145–149.PubMedGoogle Scholar
  192. 190.
    Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, et al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation 1994; 89: 1557–1566.PubMedGoogle Scholar
  193. 191.
    Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993–1003.PubMedGoogle Scholar
  194. 192.
    Zoldhelyi P, Webster MW, Fuster V, Grill DE, Gaspar D, Edwards SJ, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993; 88: 2015–2022.PubMedGoogle Scholar
  195. 193.
    Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622–1629.PubMedGoogle Scholar
  196. 194.
    Lee LV. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995; 75: 7–13.PubMedGoogle Scholar
  197. 195.
    GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa. Circulation 1994; 90: 1631–1637.Google Scholar
  198. 196.
    The GUSTO Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb. N Engl J Med 1996; 335: 775–782.Google Scholar
  199. 197.
    Bata I, Macfarlane M, Campeau J, Ouimet F, Panju A, Woodcock G, et al. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation-a pilot study. Circulation 1997; 96: 769–777.Google Scholar
  200. 198.
    Maraganore JM. Pre-clinical and clinical studies on hirulog: a potent and specific direct thrombin inhibitor. Adv Exp Med Biol 1993; 340: 227–236.PubMedGoogle Scholar
  201. 199.
    Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157–163.PubMedGoogle Scholar
  202. 200.
    Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW. Thrombin-specific inhibition by and slow cleavage of hirulog-l. Biochem J 1992; 287: 663–664.PubMedGoogle Scholar
  203. 201.
    Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 1995; 92: 727–733.PubMedGoogle Scholar
  204. 202.
    Bittl JA, Strony J, Brinker JA, Ahmed WA, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764–769.PubMedGoogle Scholar
  205. 203.
    Imura Y, Stassen JM, Vreys I, Lesaffre E, Gold HK, Collen D. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatoban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Thromb Haemost 1992; 68: 336–340.PubMedGoogle Scholar
  206. 204.
    Callas DD, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. Semin Thromb Hemost 1995; 21: 177–183.PubMedGoogle Scholar
  207. 205.
    Hauptmann J, Kaiser B. Anticoagulant and antithrombotic action of the factor Xa inhibitor antistasin (ATS). Thromb Res 1993; 71: 169–174.PubMedGoogle Scholar
  208. 206.
    Dunwiddie CT, Nutt EM, Vlasuk GP, Siegl PK, Schaffer LW. Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey. Thromb Haemost 1992; 67: 371–376.PubMedGoogle Scholar
  209. 207.
    Nutt EM, Jain D, Lenny AB, Schaffer L, Siegl PK, Dunwiddie CT. Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa. Arch Biochem Biophys 1991; 285: 37–44.PubMedGoogle Scholar
  210. 208.
    Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, et al. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257–262.PubMedGoogle Scholar
  211. 209.
    Crea F, Pupita G, Galassi A, Tamimi H, Kaski J, Davies G, et al. Effect of theophylline on exercise-induced myocardial ischaemia. Lancet 1989; 1: 683–686.PubMedGoogle Scholar
  212. 210.
    Pecora M, Roubin G, Cobbs B, Elllis S, Weintraub W, King S III. Presentation and late outcome of myocardial infarction in the absence of angiographically significant coronary artery disease. Am J Cardiol 1988; 62: 363–367.PubMedGoogle Scholar
  213. 211.
    Kokawa T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M, et al. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15: 504–510.PubMedGoogle Scholar
  214. 212.
    Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950–26955.PubMedGoogle Scholar
  215. 213.
    Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004–2010.PubMedGoogle Scholar
  216. 214.
    Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinol 1993; 4: 661–669.Google Scholar
  217. 215.
    Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen KS. Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. Blood Coagul Fibrinol 1994; 5: 755–760.Google Scholar
  218. 216.
    Holst J, Lindblad B, Bergqvist D, Nordfang O, Ostergaard PB, Petersen JL, et al. Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model. Haemostasis 1993; 23 (suppl 1): 112–117.PubMedGoogle Scholar
  219. 217.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/ IIIa receptors. J Am Coll Cardiol 1995; 26: 1665–1671.PubMedGoogle Scholar
  220. 218.
    Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997; 30: 149–156.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • M. Musa Khan
  • Neal S. Kleiman

There are no affiliations available

Personalised recommendations